← Human Trials & Peer-Reviewed Studies
The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
Plain-language guide to PMID 9435425 (1998): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 9435425
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 1998
- Study type
- Randomized Controlled Trial
- Authors
- Cuneo RC et al. (18 authors)
- DOI
- 10.1210/jcem.83.1.4482
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The researchers report the results of an Australian multicenter, randomized, double-blind, placebo-controlled trial of the effects of recombinant human GH treatment in adults with GH deficiency.
GH deficiency was defined as a peak serum GH of < 5 mU/liter in response to insulin-induced hypoglycemia.
Who Took Part
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
One hundred sixty-six patients (72 females and 91 males) with a mean age of 40 +/- 1 yr (+/- SEM; range 17-67 yr) were recruited.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and multicenter.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
More than one site took part, so the participants came from several places.
What Was Measured
The primary end points were biochemical responses, body composition, quality of life, and safety.
The subject headings attached to it are Analysis of Variance, Australia, Blood Pressure, Bone Density, Cholesterol, Cholesterol, HDL and Cholesterol, LDL.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The publication is from 1998 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.